Cargando…

HTA51 Challenges and Opportunities of Health Technology Assessment in Older Adult Immunization

Detalles Bibliográficos
Autores principales:	van Dorst, P, Van der Schans, J, de Waure, C, Largeron, N, Roberts, C, Beck, E, Postma, MJ, Boersma, C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747490/ http://dx.doi.org/10.1016/j.jval.2022.09.1511

Ejemplares similares

PRS27 Incorporating Heterogeneity in Risk for Infection and Disease in Cost-Effectiveness of Preventative Strategies in Older Adults
por: Zeevat, F., et al.
Publicado: (2020)

P53 The Early Lessons of COVID-19: The Need for a Broader Health-Economic Perspective
por: Schöttler, M, et al.
Publicado: (2022)

P68 Investing in the Prevention of Infectious Disease Outbreaks: Fiscal Health Modelling for Assessing the Public Investment Case
por: Schöttler, M, et al.
Publicado: (2022)

HTA26 Health Technology Assessment (HTA) Methods for Monoclonal Antibodies for Treatment and Prevention of COVID-19
por: Warttig, S, et al.
Publicado: (2022)

Disinvestment in healthcare: an overview of HTA agencies and organizations activities at European level
por: Calabrò, G. E., et al.
Publicado: (2018)

Exploratory Analysis of the Economically Justifiable Price of a Hypothetical RSV Vaccine for Older Adults in the Netherlands and the United Kingdom
por: Zeevat, F, et al.
Publicado: (2021)

Health technology assessment (HTA) increasingly important in spine research
por: van Tulder, Maurits
Publicado: (2011)

Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies
por: Makady, Amr, et al.
Publicado: (2017)

Challenges in the Evaluation of Emerging Highly Specialised Technologies: Is There a Role for Living HTA?
por: Merlin, Tracy, et al.
Publicado: (2023)

Country score tool to assess readiness and guide evidence generation of immunization programs in aging adults in Europe
por: Pham, Thi Hao, et al.
Publicado: (2023)

HTA253 Payer Perspectives on the Impact of the COVID-19 Pandemic on Health Technology Assessments (HTA) in Europe
por: Hutcheson, R, et al.
Publicado: (2022)

An EU-wide approach to HTA: An irrelevant development or an opportunity not to be missed?
por: Kanavos, Panos, et al.
Publicado: (2019)

How can the results of Health Technology Assessment (HTA) evaluations applied to vaccinations be communicated to decision-makers and stakeholders? The ISPOR Rome Chapter Project
por: GASPARINI, R., et al.
Publicado: (2015)

Investing in the Prevention of Communicable Disease Outbreaks: Fiscal Health Modelling—The Tool of Choice for Assessing Public Finance Sustainability
por: van der Schans, Simon, et al.
Publicado: (2023)

Economic evaluation of orphan drug Lutetium-Octreotate vs. Octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands
por: Hagendijk, Marije E., et al.
Publicado: (2021)

Hospital-based health technology assessment (HTA) in Finland: a case study on collaboration between hospitals and the national HTA unit
por: Halmesmäki, Esa, et al.
Publicado: (2016)

A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?
por: Allen, Nicola, et al.
Publicado: (2017)

Expanding HTA – Correcting a Misattribution, Clarifying the Scope of HTA and CEA: Comment on "Ethics in HTA: Examining the ‘Need for Expansion’"
por: Culyer, Anthony J.
Publicado: (2019)

Navigating HTA implementation: a review of Indonesia’s revised HTA guideline
por: Chavarina, Kinanti Khansa, et al.
Publicado: (2023)

Ethical analysis in HTA of complex health interventions
por: Lysdahl, Kristin Bakke, et al.
Publicado: (2016)

The development of HTA collaboration at European level and the challenge of the EU regulation
por: Ruether, A, et al.
Publicado: (2022)

Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile
por: Wang, Ting, et al.
Publicado: (2022)

GMS-HTA: Information out of the world of HTA - up-to-date, comprehensive and valid
por: Rüther, Alric
Publicado: (2005)

Use of Patient Preferences in Health Technology Assessment: Perspectives of Canadian, Belgian and German HTA Representatives
por: van Overbeeke, Eline, et al.
Publicado: (2020)

An Updated Analysis of the Impact of HPV Vaccination Based on Long-term Effectiveness in the Netherlands
por: Luttjeboer, Jos, et al.
Publicado: (2023)

Health technology assessment (HTA) and economic evaluation: efficiency or fairness first
por: Richardson, Jeff, et al.
Publicado: (2018)

Landscape analysis of health technology assessment (HTA): systems and practices in Asia
por: Teerawattananon, Yot, et al.
Publicado: (2019)

HTA Training for Healthcare Professionals: International Overview of Initiatives Provided by HTA Agencies and Organizations
por: Hoxhaj, Ilda, et al.
Publicado: (2022)

HTA challenges for personalized medicine: the case of liquid biopsy for lung cancer
por: Aguilera-Cobos, L, et al.
Publicado: (2023)

POSB425 Methodological Challenges to Coronavirus Disease (COVID-19) Evidence Generation to Inform Health Technology Assessment (HTA)
por: Rtveladze, K, et al.
Publicado: (2022)

The Impact of Brexit on Pharmaceuticals and HTA
por: Lorgelly, Paula K
Publicado: (2018)

The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders
por: Wasir, Riswandy, et al.
Publicado: (2019)

Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA)
por: Brettschneider, Christian, et al.
Publicado: (2011)

Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines
por: Lach, Krzysztof, et al.
Publicado: (2017)

HTA and National Immunisation Program: an overview of competent bodies and of the impact of HTA on the decision-making process
por: Ricciardi, W
Publicado: (2022)

How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory‐HTA parallel scientific advice
por: Tafuri, Giovanni, et al.
Publicado: (2016)

Rotavirus Vaccination of Infants Delayed and Limited within the National Immunization Programme in the Netherlands: An Opportunity Lost
por: Zeevat, Florian, et al.
Publicado: (2021)

POSC254 The Impact of COVID-19 on European HTA Decisions
por: Watson, C, et al.
Publicado: (2022)

Reconstructing the Effectiveness of Policy Measures to Avoid Next-Wave COVID-19 Infections and Deaths Using a Dynamic Simulation Model: Implications for Health Technology Assessment
por: Hagens, Arnold, et al.
Publicado: (2022)

Involving patient in the early stages of health technology assessment (HTA): a study protocol
por: Gagnon, Marie-Pierre, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7rfb3e41iscv6d783qg55kaoln